

Special Issue

Immunological Avalanches: Understanding Immune System Instability in Lupus, IgA Nephropathy, and Transplant Rejection

Message from the Guest Editors

This Special Issue aims to amalgamate the current understanding of the mechanisms by which immune homeostasis collapses into runaway inflammation in SLE, IgA nephropathy, and renal allograft rejection, as well as highlighting translational strategies to detect, intercept, and therapeutically modulate these immunological avalanches. The discovery and characterization of new therapeutic targets and strategies, including immunological avalanches, is the main topic of the Biomedicines journal.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: (A) pathogenic triggers; (B) effector cascades, e.g., complement pathways and neutrophil extracellular traps; (C) biomarkers of instability, e.g., circulating complement split products (C3a and C5a), donor-derived cell-free DNA, and cytokine signatures; and (D) therapeutic interception.

We look forward to receiving your contributions.

Guest Editors

Dr. Davide Viggiano

Department of Translational Medical Sciences, University of Campania,
80131 Naples, Italy

Dr. Giuseppe Gigliotti

Department of Nephrology and Dialysis, Eboli Hospital, 84025 Eboli,
Italy

Dr. Angelo Ferrantelli

Department of Nephrology and Dialysis, ARNAS, Palermo, Italy



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/240116

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).